What Is the Treatment for Kidney Cancer That Has Spread to the Lungs?

Treatment for kidney cancer that has spread to the lungs typically centers on systemic drug therapy, usually a combination of immunotherapy and a targeted drug given together as a first-line regimen. The lungs are one of the most common sites where renal cell carcinoma (the dominant type of kidney cancer) metastasizes, and the good news is that lung-only spread generally carries a better prognosis than metastases to the liver, bone, or brain. Depending on how many lung lesions you have, how large they are, and how quickly the disease is growing, your oncologist may also consider surgery to remove the lung nodules, focused radiation, or even a period of close monitoring before starting any drugs at all.

Why the Lungs Are a Common Destination

Renal cell carcinoma is a highly vascular tumor, meaning it has an unusually rich blood supply. Blood leaving the kidneys passes directly through the heart and into the lungs, which act as a filter for the entire venous circulation. That plumbing arrangement makes the lungs a natural landing spot for cancer cells that break free from a kidney tumor. Lung involvement can show up as scattered nodules in the lung tissue itself, deposits along the lining of the lung (the pleura), fluid collections around the lung, or even growths inside the airways.

First-Line Systemic Therapy

For most people whose kidney cancer has spread, the standard initial treatment is a combination of two drugs rather than a single agent. The two main strategies pair either two immune checkpoint inhibitors together (often called IO+IO) or one checkpoint inhibitor with a tyrosine kinase inhibitor that blocks blood-vessel growth signals in the tumor (IO+TKI). Both approaches have largely replaced the older practice of giving a TKI alone as the first treatment.

In real-world data comparing these two strategies broadly across metastatic kidney cancer, one Japanese analysis found that IO+TKI combinations produced longer progression-free survival than IO+IO combinations (roughly 16 months versus 8 months), though overall survival was similar between the groups at around four years.¹ In other words, IO+TKI kept tumors from growing for longer, but patients on IO+IO eventually caught up in terms of how long they lived overall.

When researchers looked specifically at patients whose metastases were confined to the lungs (with or without lymph node involvement), the picture was even more balanced. In a study of 132 such patients, progression-free survival was about 15 months in both the IO+IO and IO+TKI groups, and overall survival exceeded three and a half years regardless of which combination was used. Response rates were numerically higher with IO+TKI (about 64% versus 52%), but the difference was not statistically meaningful.² This suggests that for lung-predominant disease, both combination strategies perform comparably well, and the choice between them often comes down to side-effect profiles and individual patient factors rather than a clear survival advantage for one over the other.

How Risk Category Shapes the Decision

Oncologists classify metastatic kidney cancer into favorable, intermediate, and poor risk groups based on clinical features like how quickly the cancer grew, blood counts, and overall health markers. This risk grouping, developed by the International Metastatic Renal Cell Carcinoma Database Consortium, strongly influences which treatment combination your doctor recommends.

For intermediate-risk patients, real-world evidence has shown a survival difference favoring IO+TKI over IO+IO, with median overall survival reaching roughly 56 months versus 40 months.³ For poor-risk patients, however, neither combination clearly outperformed the other. And for favorable-risk disease, the picture is different again: pooled analyses across multiple major clinical trials have found that newer IO-based combinations do not consistently improve overall survival compared to single-agent TKI therapy, likely because favorable-risk tumors tend to grow slowly and respond well to anti-angiogenic drugs on their own.⁴ Since lung-only metastases are sometimes associated with more favorable biology, this distinction matters: if your risk profile is favorable and your only metastatic site is the lungs, a less aggressive treatment may be entirely reasonable.

Surgery to Remove Lung Metastases

Not everyone with kidney cancer in the lungs needs to rely solely on drugs. When the primary kidney tumor has been removed or is well controlled, only a limited number of lung nodules are present, and no cancer is detected elsewhere in the body, surgically removing the lung metastases (pulmonary metastasectomy) can produce impressively long survival.

A single-institution study spanning 25 years found that patients who had their lung metastases surgically removed achieved five-year and ten-year survival rates of about 47% and 18%, respectively, with a median survival of 39 months after lung surgery.⁵ Another analysis focused on a more carefully selected group, where the primary cancer was fully controlled and the lungs were the only metastatic site, reported even better results: five-year overall survival of 75% and ten-year survival of 59%.⁶

Two factors stood out as strong predictors of how well surgery would work. Metastases smaller than 2 centimeters did considerably better than larger ones, and a longer gap between the original kidney surgery and the appearance of lung nodules (five years or more) was associated with dramatically better three-year survival compared to a shorter interval.⁶ That time gap reflects the biology of the tumor: a cancer that took years to reappear in the lungs is behaving more slowly than one that showed up within months. The catch is that recurrence after lung surgery is common. In the 25-year series, about 70% of patients eventually developed new disease, sometimes in the lungs again and sometimes at distant sites.⁵ Still, the years of disease-free time that surgery can buy are substantial for the right patient.

Stereotactic Radiation for Lung Nodules

When surgery is not ideal, either because of the location of the nodule, the patient’s lung function, or other health issues, highly focused radiation called stereotactic body radiotherapy (SBRT) has emerged as a powerful alternative. SBRT delivers large doses of radiation to small, precisely targeted areas over just a few treatment sessions, sparing the surrounding lung tissue.

Kidney cancer has traditionally been considered resistant to conventional radiation, but SBRT’s concentrated dosing seems to overcome much of that resistance. A German multicenter study reported one-year and three-year local control rates of about 98% and 92% for lung metastases treated with SBRT, meaning the targeted nodules stayed controlled in the vast majority of patients. Three-year overall survival was roughly 44%, and side effects were mild.⁷ An Italian multicenter study that included lung metastases among other sites confirmed those local control rates and found no severe toxicities, with one-year and three-year overall survival of about 93% and 82% across the full patient group.⁸

SBRT is particularly attractive for patients with oligometastatic disease, a term describing a state where only a small number of metastases exist. A phase 2 trial treating oligometastatic kidney cancer patients with SBRT alone (no systemic drugs) found that 91% of patients remained free of systemic therapy at one year, with 100% local control and no severe toxicities.⁹ A separate phase 2 trial of metastasis-directed therapy without systemic treatment in oligometastatic clear-cell kidney cancer reinforced the idea that select patients can be managed this way, enjoying prolonged time off systemic drugs with favorable progression-free survival.¹⁰ For patients who dread the chronic side effects of systemic therapy, the prospect of treating a few lung nodules with SBRT and deferring drug treatment is genuinely appealing.

Image-Guided Ablation

Another option for small lung metastases is thermal ablation, where a needle is inserted through the skin under imaging guidance and the tumor is destroyed with heat or cold. This technique, sometimes called percutaneous ablation, is less invasive than surgery and can target metastases in the lung, liver, adrenal gland, and other locations. One study of 82 metastatic kidney cancer lesions treated with image-guided ablation (including lung and other sites) reported a technical failure rate of under 5% and a three-year overall survival rate of 76%.¹¹ Ablation works best for tumors that are small and accessible, and it can be repeated if new nodules appear later.

When Watching and Waiting Makes Sense

It might seem counterintuitive, but not all metastatic kidney cancer needs treatment right away. Some patients, especially those with favorable risk profiles, small or slow-growing lung nodules, and no symptoms, can safely undergo a period of active surveillance before starting systemic therapy. A prospective phase 2 trial confirmed that a subset of patients with metastatic kidney cancer can be safely watched before beginning treatment, allowing their oncologists to assess the tempo of the disease and avoid unnecessary drug exposure.¹²

The logic here is practical. Many systemic therapies carry meaningful side effects, and if your disease is indolent enough that it will not cause harm for months or even years, starting drugs immediately exposes you to those side effects without a clear benefit in overall outcome. Active surveillance does not mean neglect; it means regular imaging scans and blood work to track the disease, with a plan to begin treatment if the cancer starts growing faster or symptoms develop.

Second-Line and Later Treatment Options

If the first combination regimen stops working, several options exist for second-line therapy and beyond. The specific choice depends heavily on what you received first. Drugs that block the mTOR signaling pathway, such as everolimus, have been used in patients whose cancers progressed after anti-angiogenic therapy, showing improved progression-free survival compared to no active treatment.¹³ However, the landscape has shifted, and checkpoint immunotherapy (if not used first line) is often preferred in the second-line setting because of its potential for durable responses and a more tolerable side-effect profile.

A newer drug called belzutifan represents a genuinely different approach. It works by blocking a protein called HIF-2α, which kidney cancers rely on to drive their growth signals. Belzutifan is approved for patients with clear-cell kidney cancer who have already been treated with both an immune checkpoint inhibitor and a VEGF-targeting drug.¹⁴ It represents the first approved drug in its class and offers a mechanism of action that is entirely distinct from existing therapies, which matters because tumors that have become resistant to one type of drug may still be vulnerable to another.

When the Cancer Is Not Clear-Cell

Most kidney cancers are the clear-cell subtype, and nearly all the major clinical trials were designed around clear-cell disease. If your kidney cancer has a different histology, the treatment landscape gets murkier. Non-clear-cell subtypes include papillary, chromophobe, collecting duct, and several rarer variants, and they don’t all behave the same way.

Among non-clear-cell cancers that had spread, patients with chromophobe tumors have historically fared better than those with papillary or collecting duct histology.¹⁵ However, the response to modern immunotherapy varies widely by subtype. In one institutional study of nivolumab (a checkpoint inhibitor) in non-clear-cell kidney cancer, patients with unclassified histology had a response rate of about 44%, while none of the patients with papillary type 2, chromophobe, or translocation subtypes achieved an objective response.¹⁶ These numbers come from small patient groups, so they should be taken cautiously, but they underscore how much histology matters. If you have a non-clear-cell cancer that has reached the lungs, your oncologist may consider clinical trials or alternative drug combinations that have shown more promise for your specific subtype.

Managing Side Effects and Tracking Response

Whichever systemic therapy you receive, side effects are part of the equation. TKIs can cause fatigue, high blood pressure, hand-foot skin reactions, and diarrhea. Checkpoint inhibitors carry the risk of immune-related side effects where the immune system attacks healthy tissues, leading to problems in the thyroid, liver, lungs, or gut. The encouraging finding from years of clinical experience is that virtually all of these side effects can be managed effectively with supportive care, dose adjustments, or brief treatment pauses.¹⁷ What matters is catching them early and communicating openly with your care team, because unnecessary dose reductions driven by poorly managed side effects can undermine the effectiveness of treatment.

Tracking whether treatment is working relies primarily on CT scans of the chest, abdomen, and pelvis done at regular intervals. Oncologists measure your lung nodules and other tumor deposits on each scan and compare them against the baseline measurements. Even a modest early shrinkage in the total tumor size at the first follow-up scan, on the order of ten percent, has been linked to better long-term outcomes in patients on anti-angiogenic therapy.¹⁸ So even if the nodules have not dramatically melted away after the first two or three months, a trend in the right direction is a reassuring signal.

Quality of Life Under Treatment

Survival is one measure, but how you feel during treatment is another. The shift from older cytokine-based therapies toward targeted drugs and immunotherapy has brought meaningful improvements in day-to-day quality of life. In a landmark comparison, patients receiving sunitinib (a TKI) reported significantly better quality-of-life scores across multiple domains, including physical functioning and overall well-being, compared to those on the older interferon-alfa regimen, with clinically meaningful differences emerging within the first few treatment cycles.¹⁹

Later, when checkpoint immunotherapy entered the picture, the quality-of-life story got even better. In the CheckMate 025 trial, patients treated with nivolumab were significantly more likely to experience a clinically meaningful improvement in kidney-cancer-specific symptoms than those on everolimus, and the improvement came faster, at a median of under five months.²⁰ These are not abstract statistical findings; they translate to things like less fatigue, fewer disease-related symptoms, and more time feeling well enough to do what matters to you.

Why Location of Spread Matters for Prognosis

Newer prognostic models are starting to incorporate not just how many risk factors you have but where your cancer has spread. Researchers have found that adding information about metastatic sites improves the ability to predict survival beyond the standard risk-grouping systems. In a direct comparison of scoring systems, a model that accounted for both the number and distribution of metastatic sites outperformed the standard model in predicting overall survival for patients on first-line TKI therapy.²¹ For patients with lung-only disease, this is generally good news: isolated lung metastases carry a more favorable outlook than liver, brain, or bone involvement. That said, where you fall matters enough that having this conversation with your oncologist, with your specific scans and blood work in front of you, is more useful than any general statement about averages.

The Biomarker Problem

One frustration in kidney cancer treatment is the lack of reliable biomarkers to predict which drug will work best for a given patient. Unlike some other cancers where a genetic mutation or protein level clearly indicates which therapy to choose, kidney cancer has not yielded a definitive predictive test. Tumor characteristics including pathology, genomic changes, and gene-expression patterns have been extensively studied but have not produced robust markers that reliably guide treatment selection.²² Treatment decisions therefore continue to rest heavily on risk group, metastatic sites, histology, patient preferences, and side-effect tolerance. Research into biomarkers remains one of the most active areas in kidney cancer science, and clinical trials increasingly collect tissue and blood samples to help solve this puzzle, but for now, treatment selection is more art than algorithm.